After completing a review of its drug portfolio, Swiss drug giant Novartis AG is dropping about 20 percent of its drug-research projects, according to Bloomberg.
Pharmacy
A federal court in New Jersey ruled that a patent on Johnson & Johnson's highly profitable prostate cancer treatment Zytiga is invalid, clearing the way for generic competition, according to STAT.
Four pharmacy benefit managers — UnitedHealth's OptumRx, CVS Caremark, Express Scripts and Prime Therapeutics — must face a lawsuit over their roles in the skyrocketing price of EpiPen, a federal judge ruled Oct. 26, according to Bloomberg.
As disruptors continue to push into the healthcare arena and pressure accumulates to reduce drug prices, pharmaceutical companies are taking steps to remain competitive and enhance their drug pipelines.
The American Medical Association urged the Federal Trade Commission to take action against the major drug companies and pharmacy benefit managers they say are contributing to the skyrocketing prices of insulin, according to The Hill.
Advertisement
Nearly 50 percent of consumers have walked out of a pharmacy without the medicine prescribed by their physician because it was too expensive, according to a new survey by DrFirst.
Abbott Laboratories and Abbvie Inc. will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to physicians and employed unlawful marketing tactics to bolster prescriptions of its cholesterol drug TriCor, the Department of Justice said in…
President Donald Trump's proposal to lower Medicare drug costs, which was first announced Oct. 25, is drawing resistance from various segments of the healthcare industry — including physicians, pharma companies and hospitals, according to Politico.
Eli Lilly & Co. is the latest drugmaker to bet on gene-silencing technology, spending $100 million for a stake in Dicerna Pharmaceuticals, Reuters reports.
After working on separate medications for years, pharma giants Novartis AG and Pfizer will collaborate to develop combination treatments for a liver disease. Experts predict a highly lucrative market for such treatments, Reuters reports.